Claritev (NYSE:CTEV – Get Free Report) CEO Travis Dalton purchased 5,110 shares of Claritev stock in a transaction on Wednesday, November 11th. The shares were purchased at an average cost of $29.34 per share, with a total value of $149,927.40. Following the transaction, the chief executive officer owned 57,432 shares in the company, valued at approximately $1,685,054.88. The trade was a 9.77% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Travis Dalton also recently made the following trade(s):
- On Thursday, August 27th, Travis Dalton purchased 4,500 shares of Claritev stock. The shares were acquired at an average cost of $38.81 per share, with a total value of $174,645.00.
- On Friday, August 28th, Travis Dalton acquired 1,950 shares of Claritev stock. The stock was acquired at an average price of $38.48 per share, for a total transaction of $75,036.00.
Claritev Trading Down 0.0%
Shares of NYSE CTEV traded down $0.01 during midday trading on Friday, reaching $26.89. The company’s stock had a trading volume of 175,323 shares, compared to its average volume of 312,186. The stock has a 50 day simple moving average of $26.18 and a 200-day simple moving average of $25.46. The stock has a market capitalization of $455.79 million, a price-to-earnings ratio of -1.64 and a beta of 1.05. Claritev has a fifty-two week low of $11.50 and a fifty-two week high of $55.50.
Claritev (NYSE:CTEV – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported $1.77 EPS for the quarter, topping the consensus estimate of ($3.68) by $5.45. The business had revenue of $268.31 million for the quarter. As a group, equities analysts anticipate that Claritev will post -15.02 EPS for the current year.
Hedge Funds Weigh In On Claritev
Institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its stake in shares of Claritev by 2.5% during the first quarter. Bank of New York Mellon Corp now owns 18,111 shares of the company’s stock worth $296,000 after purchasing an additional 447 shares during the period. RBF Capital LLC lifted its holdings in Claritev by 0.8% during the 1st quarter. RBF Capital LLC now owns 135,314 shares of the company’s stock worth $2,211,000 after purchasing an additional 1,127 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in Claritev in the 2nd quarter valued at $44,000. State of Wyoming boosted its stake in Claritev by 239.2% in the 1st quarter. State of Wyoming now owns 2,018 shares of the company’s stock valued at $33,000 after purchasing an additional 1,423 shares during the period. Finally, Public Employees Retirement System of Ohio acquired a new position in Claritev in the 1st quarter valued at $38,000. 87.15% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on CTEV. Wall Street Zen upgraded shares of Claritev from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Barclays restated an “overweight” rating and issued a $40.00 price objective (up from $28.00) on shares of Claritev in a report on Thursday, August 20th. Piper Sandler reaffirmed an “overweight” rating and issued a $73.00 target price on shares of Claritev in a research report on Wednesday, August 12th. Wells Fargo & Company upped their target price on Claritev from $22.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 12th. Finally, Citigroup reissued a “buy” rating and set a $45.00 price target (up from $40.00) on shares of Claritev in a research report on Monday, August 10th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $44.83.
Check Out Our Latest Research Report on CTEV
About Claritev
Claritev, formerly known as MultiPlan, provides technology-enabled services intended to help manage healthcare costs and support payment accuracy. Its offerings include access to provider networks, claims and payment solutions, and data analytics for evaluating healthcare costs and utilization. The company serves health plans, self-insured employers, third-party administrators and other participants in the U.S. healthcare system. Its services are designed to help customers identify cost-management opportunities and support more efficient healthcare transactions.
Further Reading
- Five stocks we like better than Claritev
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Claritev Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Claritev and related companies with MarketBeat.com's FREE daily email newsletter.
